PharmaDrug’s Cepharanthine Shows Potential Against Monkeypox

Pharmadrug (TSE:PHRX) has released an update.

PharmaDrug’s subsidiary Sairiyo Therapeutics has reported that cepharanthine, a component of their PD-001 drug, shows promise in binding to key proteins of the monkeypox virus, which could aid in the development of new treatments. The company is cautiously optimistic about PD-001’s potential as a multi-indication antiviral and is proceeding to Phase 1 clinical trials for its application in medical countermeasures and cancer, without claiming current efficacy in treating monkeypox.

For further insights into TSE:PHRX stock, check out TipRanks’ Stock Analysis page.